EXHIBIT 99.1
![]() |
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine |
Weston, FL; September 5, 2023 – ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine announces positive primary data outcomes in the CHAMPION-1 clinical trial conducted at University Hospital Southampton (UK) and University of Oxford (UK).
Stephanie Noviello, MD, ILiAD Chief Medical Officer remarked, “The dramatic reduction in quantitative CFU counts in BPZE1 vaccinated participants compared to placebo, over the duration of post-challenge days, reinforces the potential clinical benefit of BPZE1, confirming previously published BPZE1 results in preclinical and attenuated human challenge studies. This study was intended to inform the primary endpoint, study parameters, and sample size to power a successful Phase 3 B. pertussis human challenge study, which we are confident has now been achieved. The primary data from the CHAMPION-1 clinical study will be presented at the World Vaccine Congress on October 19th in Barcelona.” |
Contact |
Ken Solovay ILiAD Biotechnologies, LLC info@iliadbiotech.com 1-800-603-3525 |
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. |